How Weak Disclosure Can Undercut Even a Strong Patent Portfolio

Introduction : A patent is generally described as a bargain by the US Supreme Court to “the exchange that takes place when an inventor receives a limited term of protection from competitive exploitation in exchange for bringing new designs and technologies into the public domain through disclosure for the benefit of all.” Thus, providing for exclusive rights in exchange for genuine disclosure. Inventors and their advisers routinely focus on claim breadth, prior art, and prosecution strategy yet underestimate the single variable that ultimately determines whether a patent holds up, which ultimately is the quality of the specification. A poorly disclosed invention may be invented twice, because there is a lack of description in specification allowing similar inventions which would attract heavy litigation costs. The following explanation will help in understanding why a weak disclosure can undercut even a strong patent portfolio.

The Legal Requirement

Patent in every jurisdiction provides for a monopoly on adequate disclosure. In the United States, Section 112 of the Patent Act demands that a specification enables a person claiming to be an inventor, make and use so as to exploit the claimed ‘invention’ in full scope claimed in ‘written description’. Under Article - 83 of the European Patent Convention, the disclosure must be clear and complete for the invention to be monopolised out across the claimed range. India's Patents Act, 1970 mirrors this through Section 10(4) which requires the complete specification to fully and particularly describe the invention and the best method of utilising it with Section- 64(1)(h) coexisting to permit revocation where that obligation has not been met.

The consequences of falling short are three: firstly, outright invalidity; next being narrow claim construction that limits enforcement, and lastly, the easier design around for competitors who exploit the gaps between theoretical claims and actual product. Failure to cover all bases in specifications would cause a good portfolio to be redundant as ultimately it is grounded on precise language and contents of the specification. Certain case studies across jurisdictions show us how this rule affects great patent portfolios.

The U.S. Supreme Court’s Stance

Amgen had patents on antibodies that help lower bad cholesterol in patients. These patents were written in a way that covered any antibody that could bind to a protein and block its interaction with another protein. The patents listed twenty-six antibodies and gave two general methods for finding more. Sanofi, whose drug Praluent was already on the market, argued that these patents were invalid because they did not provide information to make all the antibodies they claimed to cover.

The Supreme Court, unanimously, agreed with Sanofi with Justice Gorsuch's opinion restating a rule now foundational in nature: the scope of the monopoly must match with the scope of the enabling disclosure. Allowing a skilled person towards an open-ended research programme to discover additional antibodies within the claimed functional class is not enablement; it is an invitation to the public to finish the inventor's work. Patent protection ought to be given to make and use the full scope of the claimed invention without undue experimentation. Potentially millions of antibodies were within the claim's reach and only twenty-six worked yet discovered in the specification, this gap was fatal.

The lesson extends well beyond antibodies as there is a heavy disclosure burden in the scope of functional claims in chemistry and biology claiming what a compound does rather than what it truly is. The broader the functional claim, the richer the experimental backing must be. A specification that is essentially a promissory note on future science will not survive scrutiny.

The British Common Law

Regeneron's patents related to special ‘transgenic’ mice with humanised antibody gene marketed as ‘Veloci-Mouse’ were used for experimentation. The patents claimed mice with any proportion of human variable region. The problem however was at the priority date, the company had only succeeded in producing mice with a small proportion of human gene segments in place while complete humanisation came later.

The UK Supreme Court, applying the Biogen insufficiency doctrine, held the patents were invalid as Lord Briggs articulated the principle where the patentee is entitled to a monopoly proportionate to their actual technical contribution to the art at the date of filing. Where the specification enables a partial claimed range, the claim cannot broaden to the full range. Crucially, the assessment is made only at the filing date not the date the technology eventually matures, or the date of trial. An applicant cannot file on the strength of proof-of-concept and then claim all that followed.

Thus, patent strategy relates to broad claims staked out ahead of the science they purport to cover are legally fragile claims, regardless of how the science ultimately develops.

Drafting Lessons

The most robust practice shift is to treat the specification as the primary requirement and the claims as its derivative. Every functional claim should be answered positively to the simple question, if the specification enables a skilled person to work the full scope of this claim? In case of negative answer, the claim must be narrowed and the specification enriched ideally with representative examples across the claimed range. It no longer is an option to skip these examples as they provide iron clad protection from litigation.

Avoiding use of promissory note is advisable and considering tiered claiming for a genus claim when supported by only a few species. Such claims must encapsulate a narrow claim fully anchored to the examples, alongside a broader genus claim that transparently reflects the ambitious disclosure. This preserves flexibility without staking the entire portfolio on a broad claim.

The disclosure record serves as a primary site of invalidity decision making. A portfolio audit of commercially important patents should include a review of the working examples to cross check if they actually support the claim as asserted, under the case law of each relevant jurisdiction. A patent that appears strong on the face of its portfolio but wide in its claims without any specific experimental backing is a liability in litigation defendants across jurisdiction like U.S.A., UK proceedings have all demonstrated the willingness to exploit exactly that gap.

Conclusion

Amgen, Regeneron, cases are variations on a single theme: the scope of a patent monopoly cannot lawfully exceed the scope of the inventor's actual disclosed contribution. Broad functional claims drafted ahead of enabling science do not expand a portfolio; they hollow it out. The specification is not the supporting document. It is the document. Investing in its quality is not a procedural nicety; it is the foundation on which every claim, every licensing negotiation, and every enforcement action ultimately rests.

Author :- Vijayvikrant Nag, in case of any query, contact us at Global Patent Filing or write back us via email at support@globalpatentfiling.com.

Endnotes

1. Amgen Inc. et al. v. Sanofi et al., 598 U.S. 594 (2023). The U.S. Supreme Court held that a patent specification must enable a person skilled in the art to make and use the full scope of the claimed invention without undue experimentation.
2. Regeneron Pharmaceuticals Inc v Kymab Ltd, [2020] UKSC 27. The UK Supreme Court reaffirmed the doctrine of insufficiency, holding that the breadth of a patent monopoly must correspond to the patentee's actual technical contribution at the filing date.
3. F. Hoffmann-La Roche Ltd. v. Cipla Ltd.; see also F. Hoffmann-La Roche Ltd. v. Cipla Ltd., (2009) 40 PTC 125 (Del). The Delhi High Court emphasized that patent claims must be construed in light of the complete specification and cannot extend beyond the disclosed invention.
4. Novartis AG v. Union of India, (2013) 6 SCC 1. While primarily addressing Section 3(d) of the Patents Act, the Supreme Court underscored the importance of complete disclosure and substantive support for patent claims.
5. 35 U.S.C. § 112. The provision requires that a patent specification contain a written description of the invention, enable a person skilled in the art to make and use it, and disclose the best mode contemplated by the inventor.
6. European Patent Convention. Article 83 mandates that a European patent application disclose the invention in a manner sufficiently clear and complete for it to be carried out by a person skilled in the art.
7. The Patents Act, 1970, Sections 10(4) and 64(1)(h). Section 10(4) prescribes the contents of a complete specification, while Section 64(1)(h) provides insufficiency of disclosure as a ground for revocation of a patent.
8. Terrell on the Law of Patents (Sweet & Maxwell, 2023), Chapters 8 and 9. The treatise provides a comprehensive discussion on sufficiency of disclosure, enablement, and patent specification drafting under UK patent law.